Image For Activity Cover
Medications for Alcohol and Drug Use Disorders 101: The Science of Medication Treatment
Dr. Joshua D. Lee, M.D., MSc, is an Associate Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at the NYU School of Medicine
Target Audience
This webcast was developed for judges—whether presiding over state, municipal, general jurisdiction, treatment/specialty courts and/or whether they are law trained or not).
Webinar Description
Alcohol and drug use disorders are associated with criminal behavior, arrest, and incarceration. Effective treatments are needed to reduce the burden of alcohol and drug use disorders on public safety and on the public health. Fortunately, there are three medications (antabuse, acamprosate, and naltrexone) that are FDA-approved for the treatment of alcohol dependence and three medications (methadone, buprenorphine, and naltrexone) that are approved for the treatment of opiate dependence. This presentation will review how these medications work, what the evidence of their effectiveness is, and how they are used in the community. The underutilization of these medications among individuals involved in the criminal justice system presents an exciting opportunity to expand their use and improve both public safety and public health outcomes.
Educational Objectives

At the conclusion of this activity, learners should be able to:

  • Summarize what Medication Treatment (MAT) is;
  • Describe why MAT is an effective tool, when used with substance abuse therapy, in treating alcohol and drug addiction;
  • Cite what drugs are used in MAT and define how each works
Availability: On-Demand
Expires on 06/23/2023
Cost: FREE
Credit Offered:
1 Attendance Credit
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By